Melatonin: A New-Generation Therapy for Reducing Chronic Pain and Improving Sleep Disorder-Related Pain

  • Tavleen Kaur
  • Bai-Chuang ShyuEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1099)


Melatonin is an endogenous neurohormone that is produced in most living organisms, including unicellular and multicellular organisms, plants, vertebrates, and nonvertebrate animals. In diurnal animals, endogenous melatonin functions as a neurohormone and contributes to circadian rhythms. In nocturnal animals, endogenous melatonin no longer functions as a contributor to circadian rhythms. Circadian rhythms control the timing, quantity, and quality of hormones and neurotransmitters that the body produces and eventually secretes. An imbalance of these events creates disturbances in circadian rhythm. During disturbances of circadian rhythm, the body produces hormones, chemicals, and neurotransmitters in aberrant amounts or at the wrong time of day. The human circadian system is synchronized with physiological functions and metabolism. Many studies have reported that exogenous melatonin has analgesic and neuroprotective effects in chronic pain. Considering that chronotherapy may be beneficial for the treatment of chronic pain, the present review describes the properties, possible mechanisms, and function of melatonin in chronic pain.


Melatonin Circadian rhythms Neuroprotection Chronotherapy Chronic pain Central poststroke pain 


  1. 1.
    Acuña Castroviejo D, Escames G, Carazo A, León J, Khaldy H, Reiter RJ (2002) Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr Top Med Chem 2:133–151CrossRefPubMedGoogle Scholar
  2. 2.
    Afkhamizadeh M, Sahebari M, Seyyed-hoseini S-R (2014) Morning melatonin serum values do not correlate with disease activity in rheumatoid arthritis: a cross-sectional study. Rheumatol Int 34:1145–1151CrossRefPubMedGoogle Scholar
  3. 3.
    Ahn AH, Goadsby PJ (2013) Migraine and sleep: new connections. Cerebrum: the Dana forum on brain science. Dana FoundationGoogle Scholar
  4. 4.
    Alóe F, Azevedo APD, Hasan R (2005) Sleep-wake cycle mechanisms. Rev Bras Psiquiatr 27:33–39CrossRefPubMedGoogle Scholar
  5. 5.
    Alstadhaug K, Bekkelund S, Salvesen R (2007a) Circannual periodicity of migraine? Eur J Neurol 14:983–988CrossRefPubMedGoogle Scholar
  6. 6.
    Alstadhaug K, Salvesen R, Bekkelund S (2007b) Insomnia and circadian variation of attacks in episodic migraine. Headache 47:1184–1188CrossRefPubMedGoogle Scholar
  7. 7.
    Altun A, Ugur-Altun B (2007) Melatonin: therapeutic and clinical utilization. Int J Clin Pract 61:835–845CrossRefPubMedGoogle Scholar
  8. 8.
    Ambriz-Tututi M, Granados-Soto V (2007) Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 132:273–280CrossRefPubMedGoogle Scholar
  9. 9.
    Areti A, Yerra VG, Naidu V, Kumar A (2014) Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol 2:289–295CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Arreola-Espino R, Urquiza-Marín H, Ambriz-Tututi M, Araiza-Saldaña CI, Caram-Salas NL, Rocha-González HI, Mixcoatl-Zecuatl T, Granados-Soto V (2007) Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur J Pharmacol 577:203–210CrossRefPubMedGoogle Scholar
  11. 11.
    Balzer I, Höcker B, Kapp H, Bartolomaeus B (2000) Occurrence and comparative physiology of melatonin in evolutionary diverse organisms. In: Driessche TV, Guisset JL, Petiau-de Vries GM (eds) The redox state and circadian rhythms. Springer, DordrechtGoogle Scholar
  12. 12.
    Barrett T, Kent S, Voudouris N (2000) Does melatonin modulate beta-endorphin, corticosterone, and pain threshold? Life Sci 66:467–476CrossRefPubMedGoogle Scholar
  13. 13.
    Bolten W, Gross M, Brabant T, Weck V, Labenz J (2013) Individual pain treatment with NSAIDs. MMW Fortschr Med 155(59–60):62Google Scholar
  14. 14.
    Bondi CD, Mckeon RM, Bennett JM, Ignatius PF, Brydon L, Jockers R, Melan MA, Witt-Enderby PA (2008) MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation. J Pineal Res 44:288–298CrossRefPubMedGoogle Scholar
  15. 15.
    Bonmati-Carrion MA, Arguelles-Prieto R, Martinez-Madrid MJ, Reiter R, Hardeland R, Rol MA, Madrid JA (2014) Protecting the melatonin rhythm through circadian healthy light exposure. Int J Mol Sci 15:23448–23500CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Budhiraja S, Singh J (2005) Adjuvant effect of melatonin on anesthesia induced by thiopental sodium, ketamine, and ether in rats. Methods Find Exp Clin Pharmacol 27:697–700CrossRefPubMedGoogle Scholar
  17. 17.
    Buscemi N, Vandermeer B, Hooton N, Pandya r, Tjosvold l, Hartling l, Vohra s, Klassen t P, Baker G (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385–393CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Callebert J, Jaunay J, Jallon J (1991) Control of Drosophila biorhythms. Adv Pineal Res 5:81–84Google Scholar
  19. 19.
    Callsen-Cencic P, Hoheisel U, Kaske A, Mense S, Tenschert S (1999) The controversy about spinal neuronal nitric oxide synthase: under which conditions is it up-or downregulated? Cell Tissue Res 295:183–194CrossRefPubMedGoogle Scholar
  20. 20.
    Caumo W, Levandovski R, Hidalgo MPL (2009) Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. J Pain 10:100–108CrossRefPubMedGoogle Scholar
  21. 21.
    Caumo W, Torres F, Moreira NLJR, Auzani JA, Monteiro CA, Londero G, Ribeiro DF, Hidalgo MPL (2007) The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 105:1263–1271CrossRefPubMedGoogle Scholar
  22. 22.
    Cavaletti G, Carozzi V, Chiorazzi A, Oggioni N, Rodriguez-Menendez V, Avezza F, Marmiroli P (2013) Chemotherapy-induced peripheral neuropathy in immunodeficient mice: new useful ready-to-use animal models. Ital J Anat Embryol 118:51Google Scholar
  23. 23.
    Chang F-Y (2014) Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments. World J Gastroenterol 20:2499CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen C-Q, Fichna J, Bashashati M, LI Y-Y, Storr M (2011) Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 17:3888CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chiang RPY, Huang CT, Tsai YJ (2013) Melatonin reduces median nerve injury-induced mechanical hypersensitivity via inhibition of microglial p38 mitogen-activated protein kinase activation in rat cuneate nucleus. J Pineal Res 54:232–244CrossRefPubMedGoogle Scholar
  26. 26.
    Costigan M, Woolf CJ (2000) Pain: molecular mechanisms. J Pain 1:35–44CrossRefPubMedGoogle Scholar
  27. 27.
    Cutolo M, Maestroni G (2005) The melatonin-cytokine connection in rheumatoid arthritis. Ann Rheum Dis 64:1109–1111CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cutolo M, Maestroni G, Otsa K, Aakre O, Villaggio B, Capellino S, Montagna P, Fazzuoli L, Veldi T, Peets T (2005) Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann Rheum Dis 64:212–216CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Danilov A, Kurganova J (2016) Melatonin in chronic pain syndromes. Pain and therapy 5:1–17CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    De Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A, Machado CB, Xavier F, De Souza ICC, Deitos A, Torres IL (2014) Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 15:40CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Demisch L, Demisch K, Nickelsen T (1988) Influence of dexamethasone on nocturnal melatonin production in healthy adult subjects. J Pineal Res 5:317–322CrossRefPubMedGoogle Scholar
  32. 32.
    Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G (2007) Hypothalamic activation in spontaneous migraine attacks. Headache 47:1418–1426PubMedGoogle Scholar
  33. 33.
    Desler C, Lillenes MS, Tønjum T, Rasmussen LJ (2017) The role of mitochondrial dysfunction in the progression of Alzheimer’s disease. Curr Med Chem 24:1–10Google Scholar
  34. 34.
    Doghramji K (2007) Melatonin and its receptors: a new class of sleep-promoting agents. J Clin sleep Med 3:S17PubMedPubMedCentralGoogle Scholar
  35. 35.
    El-Shenawy SM, Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS (2002) Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacol Res 46:235–243CrossRefPubMedGoogle Scholar
  36. 36.
    Engstrøm M, Hagen K, Bjørk MH, Stovner LJ, Gravdahl GB, Stjern M, Sand T (2013) Sleep quality, arousal and pain thresholds in migraineurs: a blinded controlled polysomnographic study. J Headache Pain 14:12CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ennis ZN, Dideriksen D, Vægter HB, Handberg G, Pottegård A (2016) Acetaminophen for chronic pain: a systematic review on efficacy. Basic Clin Pharmacol Toxicol 118:184–189CrossRefPubMedGoogle Scholar
  38. 38.
    Esposito E, Paterniti I, Mazzon E, Bramanti P, Cuzzocrea S (2010) Melatonin reduces hyperalgesia associated with inflammation. J Pineal Res 49:321–331CrossRefPubMedGoogle Scholar
  39. 39.
    Fingland R, Cronin A, Keifer J, Shaheen J, Davies M, Bixler E (1999) Postoperative REM sleep inhibition: association with pain or cortisol? Reg Anesth Pain Med 24:4Google Scholar
  40. 40.
    Galley HF, Mccormick B, Wilson KL, Lowes DA, Colvin L, Torsney C (2017) Melatonin limits paclitaxel-induced mitochondrial dysfunction in vitro and protects against paclitaxel-induced neuropathic pain in the rat. J Pineal Res 63:e12444CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Gogenur I (2010) Postoperative circadian disturbances. Dan Med Bull 57:B4205PubMedGoogle Scholar
  42. 42.
    Gögenur I, Wildschiøtz G, Rosenberg J (2007) Circadian distribution of sleep phases after major abdominal surgery. Br J Anaesth 100:45–49CrossRefPubMedGoogle Scholar
  43. 43.
    Gonçalves AL, Ferreira AM, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MFP (2016) Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 87:1127–1132CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Govitrapong P, Pariyanonth M, Ebadi M (1992) The presence and actions of opioid receptors in bovine pineal gland. J Pineal Res 13:124–132CrossRefPubMedGoogle Scholar
  45. 45.
    Grigg-Damberger MM, Ianakieva D (2017) Poor quality control of over-the-counter melatonin: what they say is often not what you get. J Clin Sleep Med 13:163CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L (2013) A possible new option for migraine management: agomelatine. Clin Neuropharmacol 36:65–67CrossRefPubMedGoogle Scholar
  47. 47.
    Hansson P (2004) Post-stroke pain case study: clinical characteristics, therapeutic options and long-term follow-up. Eur J Neurol 11:22–30CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Hardeland R (1996) Ubiquitous melatonin-presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol 2:25–45Google Scholar
  49. 49.
    Hardeland R (1999) Melatonin and 5-methoxytryptamine in non-metazoans. Reprod Nutr Dev 39:399–408CrossRefPubMedGoogle Scholar
  50. 50.
    Hardeland R, Poeggeler B (2003) Non-vertebrate melatonin. J Pineal Res 34:233–241CrossRefPubMedGoogle Scholar
  51. 51.
    Hernández-Pacheco A, Araiza-Saldaña CI, Granados-Soto V, Mixcoatl-Zecuatl T (2008) Possible participation of the nitric oxide-cyclic GMP-protein kinase G-K+ channels pathway in the peripheral antinociception of melatonin. Eur J Pharmacol 596:70–76CrossRefPubMedGoogle Scholar
  52. 52.
    Hussain SAR, Al-Khalifa II, Jasim NA, Gorial FI (2011) Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 50:267–271CrossRefPubMedGoogle Scholar
  53. 53.
    Ismail SA, Mowafi HA (2009) Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 108:1146–1151CrossRefPubMedGoogle Scholar
  54. 54.
    Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:769–772CrossRefPubMedGoogle Scholar
  55. 55.
    Kalsbeek A, Palm I, La Fleur S, Scheer F, Perreau-Lenz S, Ruiter M, Kreier F, Cailotto C, Buijs R (2006) SCN outputs and the hypothalamic balance of life. J Biol Rhythm 21:458–469CrossRefGoogle Scholar
  56. 56.
    Kärkelä J, Vakkuri O, Kaukinen S, Huang WQ, Pasanen M (2002) The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand 46:30–36CrossRefPubMedGoogle Scholar
  57. 57.
    Kavaliers M (1989) β-Funaltrexamine disrupts the day-night rhythm of nociception in mice. Brain Res Bull 22:783–785CrossRefPubMedGoogle Scholar
  58. 58.
    Kawabata A, Manabe S, Manabe Y, Takagi H (1994) Effect of topical administration of l-arginine on formalin-induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation. Br J Pharmacol 112:547–550CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Kelman L, Rains JC (2005) Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache 45:904–910CrossRefPubMedGoogle Scholar
  60. 60.
    Khaldy H, León J, Escames G, Bikjdaouene L, García JJ, Acuña-Castroviejo D (2002) Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology 75:201–208CrossRefPubMedGoogle Scholar
  61. 61.
    Kilic Ü, Kilic E, Reiter RJ, Bassetti CL, Hermann DM (2005) Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res 38:67–71CrossRefPubMedGoogle Scholar
  62. 62.
    Klerman EB, Goldenberg DL, Brown EN, Maliszewski AM, Adler GK (2001) Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 86:1034–1039PubMedGoogle Scholar
  63. 63.
    Klit H, Finnerup NB, Jensen TS (2009) Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol 8:857–868CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Klit H, Hansen AP, Marcussen NS, Finnerup NB, Jensen TS (2014) Early evoked pain or dysesthesia is a predictor of central poststroke pain. Pain 155:2699–2706CrossRefPubMedGoogle Scholar
  65. 65.
    Laurido C, Pelissier T, Soto-Moyano R, Valladares L, Flores F, Hernández A (2002) Effect of melatonin on rat spinal cord nociceptive transmission. Neuroreport 13:89–91CrossRefPubMedGoogle Scholar
  66. 66.
    Leon J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ (2005) Melatonin mitigates mitochondrial malfunction. J Pineal Res 38:1–9CrossRefPubMedGoogle Scholar
  67. 67.
    Li S-R, Wang T, Wang R, Dai X, Chen Q (2005) Melatonin enhances antinociceptive effects of δ-, but not μ-opioid agonist in mice. Brain Res 1043:132–138CrossRefPubMedGoogle Scholar
  68. 68.
    Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ (1984) Effects of melatonin on human mood and performance. Brain Res 323:201–207CrossRefPubMedGoogle Scholar
  69. 69.
    Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F (1998) Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 16:27–33CrossRefPubMedGoogle Scholar
  70. 70.
    Liu Y, He H, Huang F (2014) Melatonin in pain modulation: analgesic or proalgesic? Pain Stud Treatment 2:50CrossRefGoogle Scholar
  71. 71.
    Liveing E (1873) On megrim, sick-headache, and some allied disorders: a contribution to the pathology of nerve-storms. Churchill, LondonGoogle Scholar
  72. 72.
    López-Canul M, Comai S, Domínguez-López S, Granados-Soto V, Gobbi G (2015) Antinociceptive properties of selective MT2 melatonin receptor partial agonists. Eur J Pharmacol 764:424–432CrossRefPubMedGoogle Scholar
  73. 73.
    Lu W, Gwee K, Moochhalla S, Ho K (2005) Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 22:927–934CrossRefPubMedGoogle Scholar
  74. 74.
    Luchetti F, Betti M, Canonico B, Arcangeletti M, Ferri P, Galli F, Papa S (2009) ERK MAPK activation mediates the antiapoptotic signaling of melatonin in UVB-stressed U937 cells. Free Radic Biol Med 46:339–351CrossRefPubMedGoogle Scholar
  75. 75.
    Luchetti F, Canonico B, Curci R, Battistelli M, Mannello F, Papa S, Tarzia G, Falcieri E (2006) Melatonin prevents apoptosis induced by UV-B treatment in U937 cell line. J Pineal Res 40:158–167CrossRefPubMedGoogle Scholar
  76. 76.
    Mahdi AA, Fatima G, Das SK, Verma NS (2011) Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys 48:82–87PubMedGoogle Scholar
  77. 77.
    Maitra S, Baidya DK, Khanna P (2013) Melatonin in perioperative medicine: current perspective. Saudi J Anaesth 7:315CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Makay B (2009) Is there a role of melatonin in the development of growing pains? Med Hypotheses 72:225CrossRefPubMedGoogle Scholar
  79. 79.
    Martin M, Macias M, Escames G, Reiter R, Agapito M, Ortiz G, Acuña-Castroviejo D (2000) Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 28:242–248CrossRefPubMedGoogle Scholar
  80. 80.
    Matsumoto M (1999) The hypnotic effects of melatonin treatment on diurnal sleep in humans. Psychiatry Clin Neurosci 53:243–245CrossRefPubMedGoogle Scholar
  81. 81.
    Mayo JC, Sainz RM, Tan D-X, Hardeland R, Leon J, Rodriguez C, Reiter RJ (2005) Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 165:139–149CrossRefPubMedGoogle Scholar
  82. 82.
    Mcintyre IM, Norman TR, Burrows GD, Armstrong SM (1993) Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans. Chronobiol Int 10:205–213CrossRefPubMedGoogle Scholar
  83. 83.
    Mondaca M, Hernández A, Valladares L, Sierralta W, Noseda R, Soto-Moyano R (2004) Involvement of melatonin metabolites in the long-term inhibitory effect of the hormone on rat spinal nociceptive transmission. Pharmacol Biochem Behav 77:275–279CrossRefPubMedGoogle Scholar
  84. 84.
    Moore RY, Speh JC (1993) GABA is the principal neurotransmitter of the circadian system. Neurosci Lett 150:112–116CrossRefPubMedGoogle Scholar
  85. 85.
    Morgan PJ, Williams LM (1996) The pars tuberalis of the pituitary: a gateway for neuroendocrine output. Rev Reprod 1:153–161CrossRefPubMedGoogle Scholar
  86. 86.
    Mowafi HA, Ismail SA (2008) Melatonin improves tourniquet tolerance and enhances postoperative analgesia in patients receiving intravenous regional anesthesia. Anesth Analg 107:1422–1426CrossRefPubMedGoogle Scholar
  87. 87.
    Muñóz-Hoyos A, Fernández-García J, Molina-Carballo A, Macias M, Escames G, Ruiz-Cosano C, Acuña-Castroviejo D (2000) Effect of clonidine on plasma ACTH, cortisol and melatonin in children. J Pineal Res 29:48–53CrossRefPubMedGoogle Scholar
  88. 88.
    Murphy PJ, Myers BL, Badia P (1996) Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav 59:133–139CrossRefPubMedGoogle Scholar
  89. 89.
    Naguib M, Gottumukkala V, Goldstein PA (2007) Melatonin and anesthesia: a clinical perspective. J Pineal Res 42:12–21CrossRefPubMedGoogle Scholar
  90. 90.
    Nahleh Z, Pruemer J, Lafollette J, Sweany S (2010) Melatonin, a promising role in taxane-related neuropathy. Clin Med Insights Oncol 4., CMO:S4132CrossRefGoogle Scholar
  91. 91.
    Naseem M, Parvez S (2014) Role of melatonin in traumatic brain injury and spinal cord injury. Sci World J 2014:586270CrossRefGoogle Scholar
  92. 92.
    Noseda R, Hernández A, Valladares L, Mondaca M, Laurido C, Soto-Moyano R (2004) Melatonin-induced inhibition of spinal cord synaptic potentiation in rats is MT 2 receptor-dependent. Neurosci Lett 360:41–44CrossRefPubMedGoogle Scholar
  93. 93.
    Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G (2009) Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 47:82–96CrossRefPubMedGoogle Scholar
  94. 94.
    Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, Cardinali DP (2008) Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 85:335–353CrossRefPubMedGoogle Scholar
  95. 95.
    Park HJ (2014) Chemotherapy induced peripheral neuropathic pain. Korean J Anesthesiol 67:4–7CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Pasternak GW (2007) When it comes to opiates, just say NO. J Clin Invest 117:3185–3187CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Patel T, Kurdi MS (2015) A comparative study between oral melatonin and oral midazolam on preoperative anxiety, cognitive, and psychomotor functions. J Anaesthesiol Clin Pharmacol 31:37CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Paul KN, Losee-Olson S, Pinckney L, Turek FW (2009) The ability of stress to alter sleep in mice is sensitive to reproductive hormones. Brain Res 1305:74–85CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Peres M, Gonçalves A (2013) Double-blind, placebo controlled, randomized clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. Neurology 80:S40.005Google Scholar
  100. 100.
    Perissin L, Boccalon S, Scaggiante B, Petrelli L, Ortolani F, Porro CA (2004) Diurnal changes of tonic nociceptive responses in mice: evidence for a proalgesic role of melatonin. Pain 110:250–258CrossRefPubMedGoogle Scholar
  101. 101.
    Phansuwan-Pujito P, Ebadi M, Govitrapong P (2006) Immunocytochemical characterization of delta-opioid and mu-opioid receptor protein in the bovine pineal gland. Cells Tissues Organs 182:48–56CrossRefPubMedGoogle Scholar
  102. 102.
    Pickard GE (1987) Circadian rhythm of nociception in the golden hamster. Brain Res 425:395–400CrossRefPubMedGoogle Scholar
  103. 103.
    Poeggeler B, Balzer I, Hardeland R, Lerchl A (1991) Pineal hormone melatonin oscillates also in the dinoflagellate Gonyaulax polyedra. Naturwissenschaften 78:268–269CrossRefGoogle Scholar
  104. 104.
    Ray M, Mediratta P, Mahajan P, Sharma K (2004) Evaluation of the role of melatonin in formalin-induced pain response in mice. Indian J Med Sci 58:122PubMedGoogle Scholar
  105. 105.
    Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-BURILLO S (2002) Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54:1299–1321CrossRefPubMedGoogle Scholar
  106. 106.
    Rosenstein RE, Cardinali DP (1986) Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Res 398:403–406CrossRefPubMedGoogle Scholar
  107. 107.
    Rudra DS, Pal U, Maiti NC, Reiter RJ, Swarnakar S (2013) Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J Pineal Res 54:398–405CrossRefPubMedGoogle Scholar
  108. 108.
    Sahota P (2003) Morning headaches in patients with sleep disorders. Sleep Med 4(5):377.CrossRefPubMedGoogle Scholar
  109. 109.
    Schernhammer E, Schulmeister K (2004) Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer 90:941CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Shavali S, Ho B, Govitrapong P, Sawlom S, Ajjimaporn A, Klongpanichapak S, Ebadi M (2005) Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of β-endorphin an endogenous opioid. Brain Res Bull 64:471–479CrossRefPubMedGoogle Scholar
  111. 111.
    Shin DJ, Jeong CW, Lee SH, Yoon MH (2011) Receptors involved in the antinociception of intrathecal melatonin in formalin test of rats. Neurosci Lett 494:207–210CrossRefPubMedGoogle Scholar
  112. 112.
    Siah KTH, Wong RKM, Ho KY (2014) Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol 20:2492CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY (2005) Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 54:1402–1407CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Srinivasan V, Lauterbach EC, HO KY, Acuña-Castroviejo D, Zakaria R, Brzezinski A (2012) Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol 10:167–178CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Srinivasan V, Pandi-Perumal SR, Spence DW, Moscovitch A, Trakht I, Brown GM, Cardinali DP (2010) Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull 81:362–371CrossRefPubMedGoogle Scholar
  116. 116.
    Srinivasan V, Spence DW, Pandi-Perumal SR, Brown GM, Cardinali DP (2011) Melatonin in mitochondrial dysfunction and related disorders. Int J Alzheimers Dis 2011:326320PubMedPubMedCentralGoogle Scholar
  117. 117.
    Srinivasan V, Zakaria R, Singh HJ, Acuna-Castroviejo D (2013) Melatonin and its agonists in pain modulation and its clinical application. Arch Ital Biol 150:274–292Google Scholar
  118. 118.
    Starobova H, Vetter I (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 10:174CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Stoschitzky K, Sakotnik A, Lercher P, Zweiker R, Maier R, Liebmann P, Lindner W (1999) Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 55:111–115CrossRefPubMedGoogle Scholar
  120. 120.
    Sultan SS (2010) Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth 4:169CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Tabeeva G, Sergeev A, Gromova S (2011) Possibilities of preventive treatment of migraine with the MT1-and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan). Zh Nevrol Psikhiatr Im S S Korsakova 111:32–36PubMedGoogle Scholar
  122. 122.
    Ulugol A, Dokmeci D, Guray G, Sapolyo N, Ozyigit F, Tamer M (2006) Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: possible involvements of the L-arginine–NO pathway and opioid system. Life Sci 78:1592–1597CrossRefPubMedGoogle Scholar
  123. 123.
    Van Den Heuvel CJ, Ferguson SA, Macchi MM, Dawson D (2005) Melatonin as a hypnotic: con. Sleep Med Rev 9:71–80CrossRefPubMedGoogle Scholar
  124. 124.
    Vijayalaxmi, Thomas CRJR, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601CrossRefPubMedGoogle Scholar
  125. 125.
    Wang S, Tian Y, Song L, Lim G, Tan Y, You Z, Chen L, Mao J (2012) Exacerbated mechanical hyperalgesia in rats with genetically predisposed depressive behavior: role of melatonin and NMDA receptors. Pain 153:2448–2457CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Weaver DR, Dallmann R (n.d.) Melatonin receptors: past, present and futureGoogle Scholar
  127. 127.
    Weaver DR, Rivkees SA, Reppert SM (1989) Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J Neurosci 9:2581–2590CrossRefPubMedGoogle Scholar
  128. 128.
    Wiech K, Tracey I (2009) The influence of negative emotions on pain: behavioral effects and neural mechanisms. NeuroImage 47:987–994CrossRefPubMedGoogle Scholar
  129. 129.
    Wikner J, Hirsch U, Wetterberg L, Röjdmark S (1998) Fibromyalgia—a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol 49:179–183CrossRefGoogle Scholar
  130. 130.
    Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I (2011) Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 51:270–277CrossRefPubMedGoogle Scholar
  131. 131.
    Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28CrossRefPubMedGoogle Scholar
  132. 132.
    Xiong X-C, Zhu Y, Ge R, Liu L-F, Yuan W (2015) Effect of melatonin on the extracellular-regulated kinase signal pathway activation and human osteoblastic cell line hFOB 1.19 proliferation. Int J Mol Sci 16:10337–10353CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Xu R, Wu X, Di A, Xu J, Pang C, Pang S, Meng Z, Lu G-W, Wang Q, Wu Y (2000) Receptor and non-receptor mediated actions of melatonin. Neurosignals 9:53–75CrossRefGoogle Scholar
  134. 134.
    Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F (2010) Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative Period: A qualitative systematic review of randomized trials. Anesthesiology 113:968–976CrossRefPubMedGoogle Scholar
  135. 135.
    Yu C, Wu G, Xu S, Chen C (2000) Melatonin influences the release of endogenous opioid peptides in rat periaqueductal gray. Sheng Li Xue Bao 52:207–210PubMedGoogle Scholar
  136. 136.
    Zahn PK, Lansmann T, Berger E, Speckmann EJ, Musshoff U (2003) Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: implications for pain modulation. J Pineal Res 35:24–31CrossRefPubMedGoogle Scholar
  137. 137.
    Zhu C, Xu Y, Duan Y, LI W, Zhang L, Huang Y, Zhao W, Wang Y, Li J, Feng T (2017) Exogenous melatonin in the treatment of pain: a systematic review and meta-analysis. Oncotarget 8:100582PubMedPubMedCentralGoogle Scholar
  138. 138.
    Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor P (2012) Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol 63:641–647PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Division of Neuroscience, Institute of Biomedical Sciences, Academia SinicaTaipeiTaiwan
  2. 2.Institute of Biomedical Sciences, Academia SinicaTaipeiTaiwan

Personalised recommendations